- 279 Downloads
Pravastatin is an HMG-CoA reductase inhibitor which lowers plasma cholesterol levels by inhibiting de novo cholesterol synthesis.
Pravastatin produces consistent dose-dependent reductions in both total and low density lipoprotein (LDL)-cholesterol levels in patients with primary hyper-cholesterolaemia. Favourable changes in other parameters such as total triglyceride and high density lipoprotein (HDL)-cholesterol levels are generally modest. Combination therapy with other antihyperlipidaemic agents such as cholestyramine further enhances the efficacy of pravastatin in patients with severe dyslipidaemias.
Available data suggest that pravastatin is effective in elderly patients and in patients with hypercholesterolaemia secondary to diabetes mellitus or renal disease.
The benefit of cholesterol-lowering in terms of patient outcomes is currently an area of considerable interest. Recently completed regression studies (PLAC I, PLACII, KAPS and REGRESS) show that pravastatin slows progression of atherosclerosis and lowers the incidence of coronary events in patients with mild to moderately severe hypercholesterolaemia and known coronary heart disease. Large scale primary (WOSCOPS) and secondary (CARE) prevention studies, moreover, demonstrate that pravastatin has beneficial effects on coronary morbidity and mortality. In WOSCOPS, all-cause mortality was reduced by 22%.
Pravastatin is generally well tolerated by most patients (including the elderly), as evidenced by data from studies of up to 5 years in duration. As with other HMG-CoA reductase inhibitors, myopathy occurs rarely (<0.1% of patients treated with pravastatin); approximately 1 to 2% of patients may present with raised serum levels of hepatic transaminases.
Thus, with its favourable effects on cardiovascular morbidity/mortality and total mortality, pravastatin should be considered a first-line agent in patients with elevated cholesterol levels, multiple risk factors or coronary heart disease who are at high risk of cardiovascular morbidity.
Pravastatin inhibits HMG-CoA reductase, the enzyme which catalyses the rate-limiting step within the cholesterol biosynthetic pathway. By inhibiting de novo cholesterol production and reducing intracellular cholesterol stores, pravastatin stimulates the synthesis and activity of low density lipoprotein (LDL) receptors, thereby enhancing the clearance of atherogenic LDL-cholesterol. In vitro and in vivo data indicate that pravastatin exhibits hepatocellular tissue selectivity, with greatest inhibition of cholesterol synthesis occurring in the liver.
In hypercholesterolaemic patients, pravastatin produces consistent changes in total cholesterol, LDL-cholesterol, high density lipoprotein (HDL)-cholesterol and triglyceride levels; its effects on lipoprotein(a) are, however, variable.
Hypercholesterolaemic patients treated with pravastatin 10 to 20 mg/day also show decreases in apolipoprotein B (the major component of LDL) of 12 to 30%. Other major proteins found in HDL (apolipoprotein AI and AII) increase by 12 to 16%, while apolipoproteins CII, CIII and E [mainly found in chylomicrons and very low density lipoprotein (VLDL)-cholesterol] are reduced by 4 to 8%.
Pravastatin slows the progression of atherosclerosis in humans and may have beneficial effects in stabilising plaques, improving endothelial dysfunction, decreasing platelet thrombus formation, improving fibrinolytic activity and reducing the incidence of transient myocardial ischaemia. The drug appears to have no effect on adrenal and gonadal hormone production, gallstone formation or sleep patterns.
Pravastatin is administered orally as the sodium salt of the active compound. It is rapidly absorbed with mean peak plasma concentrations (Cmax) occurring between 0.9 and 1.6 hours after single- or multiple-dose administration in hypercholesterolaemic patients. Dose-proportional increases in both Cmax and area under the plasma concentration-time curve were also observed. The drug has an oral bioavailability of 17%.
In healthy volunteers given intravenous pravastatin 10mg, the volume of distribution averaged 0.46 L/kg at steady-state. Approximately 50% of the drug is bound to plasma proteins. Tissue distribution studies in animals have demonstrated that pravastatin is selectively taken up by hepatic cells; negligible distribution into human breast milk has been reported.
The major metabolite of pravastatin, a 3α-hydroxy isomeric compound (SQ 31 906), has approximately one-tenth to one-fortieth of the HMG-CoA reductase inhibitory activity of pravastatin; 75% of the total inhibitory activity of pravastatin is attributable to the parent drug. Pravastatin undergoes extensive first-pass extraction in the liver (extraction ratio 0.66). It is rapidly excreted and has a terminal plasma elimination half-life of 1.3 to 2.6 hours. Approximately 70 and 20% of an oral dose is eliminated in faeces and urine, respectively, over 96 hours. In patients with renal or hepatic insufficiency, these dual routes of elimination may provide compensatory pathways for the excretion of pravastatin.
The lipid-lowering efficacy of pravastatin has been well established in several large, controlled clinical trials evaluating patients with primary or secondary hypercholesterolaemia. Recent research has focused on assessing what benefits this has for normo- or hypercholesterolaemic patients with, or at risk of, coronary heart disease (CHD).
Recently completed regression studies (PLAC I, PLAC II, KAPS, REGRESS) show that pravastatin slows the progression of atherosclerosis and lowers the incidence of coronary events in patients with mild to moderately severe hypercholesterolaemia and evident CHD. Long term primary intervention data from WOSCOPS, moreover, demonstrate that pravastatin has beneficial effects on coronary morbidity and mortality, without associated increases in non-cardiovascular mortality. Combined primary end-points of nonfatal myocardial infarction or death from CHD were significantly reduced by 31%; all-cause mortality was lowered by 22%. The risk of recurrent nonfatal myocardial infarctions or death from CHD was also significantly reduced by 24% in patients receiving pravastatin in the CARE study (a secondary intervention trial). Relative reductions in risk were unaffected by age, presence of hypertension or diabetes, gender or smoking status. At present, pravastatin is the only HMG-CoA reductase inhibitor for which primary and secondary prevention data are available.
Combination therapy with other lipid-lowering agents such as cholestyramine, ω-3 fatty acids, gemfibrozil, nicotinic acid (niacin) or probucol enhances the efficacy of pravastatin; coadministration with cholestyramine may, however, negate the beneficial effects on triglycéride levels achieved with pravastatin monotherapy. Although concomitant use of gemfibrozil or nicotinic acid with pravastatin promotes further beneficial changes in both triglyceride and HDL-cholesterol levels, this combination should be used cautiously because of the potential increased risk of myopathy.
The lipid-lowering efficacy of pravastatin in elderly patients appears similar to that observed in younger individuals. Pravastatin has been successfully used in patients with hypercholesterolaemia secondary to other disease states such as diabetes mellitus or renal disease, in patients with hypertension, and in heart and kidney transplant recipients.
Like other HMG-CoA reductase inhibitors, pravastatin is likely to be more cost effective in secondary than in primary prevention, and in higher than in lower risk patient groups. Available pharmacoeconomic data are, however, inconclusive regarding the relative cost-effectiveness of agents within this class of drugs because of the lack of long term clinical outcomes data. Analysis of WOSCOPS and CARE will address some of these issues.
Data from various short and long term (5-year) studies suggest that pravastatin is generally well tolerated by most patients, including the elderly. Commonly reported events include gastrointestinal disturbances and skin rashes.
As with other HMG-CoA reductase inhibitors, myopathy occurs rarely (in <0.1% of patients treated with pravastatin). Concomitant therapy with cyclosporin, gemfibrozil, erythromycin or nicotinic acid may enhance the risk of myopathy in patients receiving HMG-CoA reductase inhibitors. Increases in hepatic transaminases occur in 1 to 2% of patients, and routine monitoring of liver function is indicated. Cataract development and sleep disturbances have not been associated with pravastatin.
The bioavailability of pravastatin was unaffected by concomitant administration with aspirin, antacids (given 1 hour before pravastatin), cimetidine, cholestyramine (given 1 hour after or 4 hours before pravastatin), colestipol (given 1 hour after pravastatin), digoxin, warfarin, probucol or nicotinic acid. Increases in plasma pravastatin concentrations have been observed with concurrent cyclosporin therapy; reductions in pravastatin clearance have also been noted in combination with gemfibrozil.
Dosage and Administration
The recommended adult dosage of pravastatin is generally 10 to 40mg taken once daily at bedtime (or divided into two daily doses). Dosages are usually initiated at 10 to 20 mg/day; in some European countries, starting dosages of 5 mg/day are also advocated. Pravastatin should be titrated according to response at intervals of not less than 4 weeks. Lower dosages may be required in patients with a history of significant renal or hepatic dysfunction, in the elderly or in patients taking concomitant cyclosporin or gemfibrozil. Pravastatin is contraindicated in patients with active liver disease or unexplained increases in hepatic transaminase levels. There are insufficient clinical data to recommend the use of pravastatin in children.
KeywordsPravastatin Probucol Familial Combine Hyperlipidaemia Hypercholesterolaemic Patient Pravastatin Sodium
Unable to display preview. Download preview PDF.
- 7.ER Squibb & Sons Limited. Pravastatin prescribing information. Middlesex, UK, 1994-5Google Scholar
- 30.Bard JM, Parra HJ, Douste-Blazy P, et al. Changes in lipoprotein particles defined by their apolipoprotein composition on pravastatin or cholestyramine therapy. J Drug Dev 1990; 3 Suppl. 1: 111–5Google Scholar
- 39.Goto Y, Yasugi T, Goto Y, et al. Clinical evaluation of CS-514 (pravastatin) on hyperlipidemia: double blind study with clinofibrate. Clin Evaluation 1988; 16: 211–49Google Scholar
- 40.Goto Y, Yamamoto A, Matsuzawa Y, et al. Clinical usefulness of pravastatin (CS-514) in the treatment of patients with hyperlipidemia: double-blind comparison with probucol. J Clin Exp Med 1988; 146: 927–55Google Scholar
- 41.Yoshino G, Matsushita M, Iwai M, et al. Two-year study on the effect of pravastatin (CS-514) on plasma lipoprotein and apolipoprotein concentrations in hypercholesterolemic patients. Curr Ther Res 1989; 46: 144–52Google Scholar
- 42.Ikeda T, Ochi H, Ohtani I, et al. Comparison of the effects of small doses of probucol and pravastatin on serum lipids and apolipoproteins in nonobese, non-insulin-dependent diabetes mellitus patients with hypercholesterolemia. Curr Ther Res 1992; 51: 593–9Google Scholar
- 47.Tait GW, Shepherd J. Hyperlipidaemia: its pathogenesis, clinical significance and treatment. Pharm J 1989; 242: 134–7Google Scholar
- 49.Kuroda M, Matsumoto A, Itakura H, et al. Effects of pravastatin sodium alone and in combination with cholestyramine on hepatic, intestinal and adrenal low density lipoprotein receptors in homozygous Watanabe heritable hyperlipidemic rabbits. Jpn J Pharmacol 1992; 59: 65–70PubMedCrossRefGoogle Scholar
- 50.Shiomi M, Watanabe Y, Ito Y, et al. Suppressive effect of the combination treatment with pravastatin sodium and cholestyramine of the progression of atherosclerosis and xanthoma in mature WHHL rabbits. Presented at the 8th International Symposium on Atherosclerosis, 1988 Oct 9–13; Rome, ItalyGoogle Scholar
- 68.Lacoste LL, Lam JYT, Hung J, et al. Pravachol decreases cholesterol and platelet thrombus formation in coronary patients [abstract no. 73]. Can J Cardiol 1993; 9 Suppl. E: 83EGoogle Scholar
- 80.Ito H. The effects of CS-514 (pravastatin), an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, on serum lipids and steroid hormones in the hypercholesterolemic elderly. J Clin Ther Med 1988; 4: 395–407Google Scholar
- 81.Dobs AS, Martin KM, Nazelrod B, et al. Is reduced vitamin D synthesis a complication of treatment with HMG-CoA reductase inhibitors? [abstract]. Arteriosclerosis 1988; 8: 635AGoogle Scholar
- 84.Kajiyama G, Horiuchi I, Takata K, et al. Effects of CS-514 on biliary lipid metabolism in patients with hyperlipidemia. J Clin Ther Med 1988; 4: 191–200Google Scholar
- 85.Tazuma S, Ohya T, Teramen K, et al. Effects of long-term treatment with low-dose pravastatin, a competitive inhibitor of hydroxymethylglutaryl coenzyme A reductase, on biliary lipid metastability in patients with hypercholesterolemia [abstract no. 1005]. Hepatology 1993; 18: 308ACrossRefGoogle Scholar
- 86.Bär PR, Bredman JJ, Koot RW. Simvastatin and lovastatin, but not pravastatin, induce myopathy in young rats [abstract no. 131]. EurJ Clin Invest 1993; 23 Suppl. 1: A24Google Scholar
- 95.Eckernäs S-Å, Roos B-E, Kvidal P, et al. The effects of simvastatin and pravastatin on objective and subjective measures of nocturnal sleep: a comparison of two structurally different HMG CoA reductase inhibitors in patients with primary moderate hypercholesterolaemia. Br J Clin Pharmac 1993; 35: 284–9Google Scholar
- 98.Katznelson S, Kobashigawa JA. Dual roles of HMG-CoA reductase inhibitors in solid organ transplantation: lipid lowering and immunosuppression. Kidney Int 1995; 48 Suppl. 52: S112–5Google Scholar
- 105.Sasahara K, Kawabata K. Phase 1 study of CS-514, an inhibitor of HMG-CoA reductase II: pharmacokinetics of CS-514 in healthy volunteers. J Clin Ther Med 1988; 4: 45–65Google Scholar
- 107.Koga T, Kawabata K, Arai K, et al. Comparative pharmacokinetics and pharmacodynamics of pravastatin and simvastatin. Bull Mol Biol Med 1995; 20: 103–5Google Scholar
- 109.Triscari J, Pan H, De Vault A, et al. Comparative bioavailability of pravastatin following morning and evening dosing [abstract no. PIII-19J. Clin Pharmacol Ther 1991; 49: 178Google Scholar
- 112.Pan H, Fleiss P, Moore L, et al. Excretion of pravastatin, an HMG-CoA reductase inhibitor, in breast milk of lactating women. J Clin Pharmacol 1988; 28: 942Google Scholar
- 117.Squibb & Sons, Inc. Pravastatin prescribing information. New Jersey, USA, 1995Google Scholar
- 123.Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383–89Google Scholar
- 124.McGovern ME, Mellies MJ. Long-term experience with pravastatin in clinical research trials. Clin Ther 1993; 14: 57–64Google Scholar
- 132.Shepherd J, Cobbe SM, Ford I. Prevention of coronary heart disease with pravastatin [letter]. N Engl J Med 1996; 334: 1334–5Google Scholar
- 136.Mellies MJ. Ongoing and planned clinical trials for atherosclerosis prevention and regression. Curr Opin Invest Drugs 1993; 2: 529–39Google Scholar
- 138.LIPID Study Group. Design features and baseline characteristics of the LIPID (Long-Term Intervention with Pravastatin in Ischemic Disease) study: a randomized trial in patients with previous acute myocardial infarction and/or unstable angina pectoris. Am J Cardiol 1995; 76: 474–9CrossRefGoogle Scholar
- 141.PPP Project Investigators. Design, rationale, and baseline characteristics of the Prospective Pravastatin Pooling (PPP) project — a combined analysis of three large-scale randomized trials: Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID), Cholesterol and Recurrent Events (CARE), and West of Scotland Coronary Prevention Study (WOSCOPS). Am J Cardiol 1995; 76: 899–905CrossRefGoogle Scholar
- 150.Jukema JW, Bruschke AVG, van Boven AJ, et al. Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. The Regression Growth Evaluation Statin Study (REGRESS). Circulation 1995; 91: 2528–40PubMedCrossRefGoogle Scholar
- 152.Jukema JW, van Boven AJ, Reiber JHC, et al. Progression and regression of coronary atherosclerosis occur within the same patient during placebo treatment and during lipid-lowering therapy with pravastatin [abstract no. 769-2]. Program and abstracts of original contributions from the 44th Annual Scientific Session American College of Cardiology: 1995 March 19–22: New Orleans, Louisiana, USA; J Am Coll Cardiol (Feb) 1995; 281AGoogle Scholar
- 153.Jukema JW, van Boven AJ, Reiber JHC, et al. Reduction of the beneficial effect of lipid-lowering therapy by pravastatin on coronary atherosclerosis in smoking patients (abstract no. 1584]. Abstracts from the XVIIth Congress of the European Society of Cardiology: 1995 August 20–24: Amsterdam, The Netherlands; Eur Heart J 1995; 16 Suppl.: 273Google Scholar
- 157.PHYLLIS Project Group. Plaque Hypertension Lipid-Lowering Italian Study (PHYLLIS): a protocol for non-invasive evaluation of carotid atherosclerosis in hypercholesterolaemic hypertensive subjects. J Hypertens 1993; 11 Suppl. 5: S314–5Google Scholar
- 168.Kawakami Y, Tagami S, Hasegawa A, et al. Clinical efficacy of fluvastatin (XU62-320) in hyperlipidemia — a comparative study with pravastatin in a double-blind comparative method [in Japanese]. Rinsho Iyaku 1995; 11: 1679–1726Google Scholar
- 183.Davidson MH, Gwynne JT, Khachadurian AK, et al. Combination of pravastatin and probucol in the treatment of primary hypercholesterolemia. Coron Artery Dis 1991; 2: 1061–8Google Scholar
- 187.Bo M, Pernigotti L, Poli L, et al. 1991. One-year experience in the treatment of elderly hypercholesterolemic patients with pravastatin. Curr Ther Res 1991; 50: 151–8Google Scholar
- 194.Anonymous. Detection and management of lipid disorders in diabetes. Diabetes Care 1993; 16 Suppl. 2: 106–12Google Scholar
- 197.Krempf M, Berthezene F, Wemeau JL, et al. Efficacite et tolerance de la pravastatine chez des patients presentant une hypercholesterolemie associee a un diabete de type II [abstract]. Diabete Metab 1993; 19: 44Google Scholar
- 202.Tokoo M, Oguchi H, Terashima M, et al. Effects of pravastatin on serum lipids and apolipoproteins in hyperlipidemia of the nephrotic syndrome. Jpn J Nephrol 1992; 34: 397–403Google Scholar
- 203.Moorhead JF. Lipids and progressive kidney disease. Kidney Int 1991; 39 Suppl. 31: S35–40Google Scholar
- 204.Mori Y, Tsuruoka A. Effect of pravastatin on microalbuminuria in patients with non-insulin-dependent diabetes mellitus [in Japanese]. J Jpn Diabetes Soc 1992; 35: 265–6Google Scholar
- 206.Alamo C, Aranda JL, Sanchez R, et al. Treatment of proteinuria-related hyperlipidemia with pravastatin [abstract]. Kidney Int 1994; 46: 562Google Scholar
- 207.Motellón JL, Sánchez-Tomero A, Gruss E, et al. Treatment with pravastatin of hypercholesterolaemia in nephrological patients: effects on proteinuria and progression of renal failure [abstract]. Nephrol Dial Transplant 1994; 9: 962Google Scholar
- 215.Fogari R, Marasi G, Zoppi A, et al. Effects of pravastatin given every other day in dyslipidemic hypertensives treated with different antihypertensive drugs [abstract no. A62]. Am J Hypertens 1994; 7 (4 Pt 2): 48AGoogle Scholar
- 217.O’Callaghan CJ, Conway EL, Lam W, et al. Effects of pravastatin on the lipid profile of hypertensive patients receiving captopril [abstract no. 1558]. Am J Hypertens 1993; 6 (5 Pt 2): 109AGoogle Scholar
- 218.Muramatsu J, Kobayashi A, Ikeda Y, et al. Change in cardiac function after long-term treatment of hyperlipidemia by a HMG-CoA reductase inhibitor (pravastatin) in patients with hypertension and ischemic heart disease [abstract no. P979]. Jpn Circ J 1993; 57: 744Google Scholar
- 221.Watanabe M, Takatori Y, Akagi S, et al. Preliminary study on the efficacy of combination therapy with pravastatin and ursodeoxycholic acid (UDCA) in gallstone dissolution [abstract no. 2594P1. World Congress of Gastroenterology, 1994 Oct 2–7; Los Angeles, USAGoogle Scholar
- 224.Kawata S, Yamasaki E, Nagase T, et al. Long-term administration of pravastatin, a potent HMG-CoA reductase inhibitor, prolongs survival of patients with advanced hepatocellular carcinoma: a randomized controlled trial [abstract no. 476]. Hepatology 1996; 24 (4 Pt 2): 245AGoogle Scholar
- 225.Pharoah PDP, Hollingworth W. Cost effectiveness of lowering cholesterol concentration with statins in patients with and without pre-existing coronary heart disease: life table method applied to health authority population. BMJ 1996; 312: 1443–8 [letters BMJ 1996; 313: 1142–4]PubMedCrossRefGoogle Scholar
- 231.Muls E, Van Ganse E, Closon MC. Cost-effectiveness of pravastatin in secondary prevention of CHD: comparison between the US and Belgium of a projected risk model [abstract]. 66th Congress of the European Atherosclerosis Society, 1996 July 13–17; Florence, Italy: 13Google Scholar
- 232.Newman TJ, Kassler-Taub KB, Gelarden RT, et al. Safety of pravastatin in long-term clinical trials conducted in the United States. J Drug Dev 1990; 3 Suppl. 1: 275–81Google Scholar
- 234.Jungnickel PW, Cantral KA, Maloley PA. Relative safety and efficacy of pravastatin [letter]. Clin Pharm 1993; 12: 256–7Google Scholar
- 235.Decoulx E, Millaire A, De Groote P, et al. Rhabdomyolysis due to pravastatin and type 1 macrocreatine kinase [in French]. Ann Cardiol Angeiol 1993; 42: 267–9Google Scholar
- 237.Perault MC, Ladouch-Bures L, Dejean C, et al. Rhabdomyolyse associée à la prise de pravastatine (Vasten®) [letter]. Therapie 1993; 48: 483–501Google Scholar
- 238.Rosenberg AD, Neuwirth MG, Kagen LJ, et al. Intraoperative rhabdomyolysis in a patient receiving pravastatin, a 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase inhibitor. Anesth Anaig 1995; 81: 1089–91Google Scholar
- 241.Ballare M, Campanini M, Airoldi G, et al. Hepatotoxic effects of hydroxy-methyl-glutaryl-coenzyme A (HMG-CoA) reductase inhibitors. Ital J Gastroenterol 1991; 23: 281Google Scholar
- 245.Schmitt C, Schmidt J, Hockwin O. Ocular drug-safety study with the HMG-CoA reductase inhibitor pravastatin. Lens Eye Tox Res 1990; 7: 631–42Google Scholar
- 247.Thompson GR. Adverse reactions profile: 10. Simvastatin and pravastatin. Prescr J 1993; 33: 217–20Google Scholar
- 250.Olbricht C, Wanner C, Eisenhauer T, et al. Pravastatin and lovastatin pharmacokinetics and pharmacodynamics in renal transplant patients receiving cyclosporine [abstract]. J Am Soc Nephrol 1995; 6: 1061Google Scholar
- 251.Castelao AM, Griñö JM, GilVernet S, et al. Effect of pravastatin in the treatment of hypercholesterolaemia after renal transplantation under cyclosporin immunosuppression. Nephrol Dial Transplant 1993; 8: 1037–8Google Scholar
- 252.Davies RA. Safety and efficacy of pravastatin after heart transplantation: preliminary patient studies [abstract]. XI International Symposium on Drugs Affecting Lipid Metabolism, 1992 May 13–16; Florence, Italy: 18Google Scholar
- 253.Valino RN, Reiss WG, Hanes D, et al. Examination of the potential interaction between HMG-CoA reductase inhibitors and cyclosporine in transplant patients [abstract no. 139]. Pharmacotherapy 1996; 16: 511Google Scholar
- 254.Feher MD, Foxton J, Banks D, et al. Long-term safety of fibrate-statin combination therapy in the treatment of hypercholesterolaemia. Br J Clin Pharmacol 1994; 37: 511PGoogle Scholar
- 258.Merck & Co, Inc. Simvastatin prescribing information. Pennsylvania, USA, 1995Google Scholar
- 259.Merck & Co, Inc. Lovastatin prescribing information. Pennsylvania, USA, 1995Google Scholar
- 267.LaRosa JC. Cholesterol-lowering and the cost-effective prevention of recurrent coronary disease. CVR & R 1996; 17: 10–28Google Scholar